The global oncology diagnostics market should reach $128.3 billion by 2025 from $86.7 billion in 2020 at a compound annual growth rate (CAGR) of 8.1% for the forecast period of 2020 to 2025.
Report Scope
This report examines the current and forecasted market potential for oncology diagnostics. It offers a detailed analysis of the market background, competitive environment, technological advancement, drivers and restraints and market growth trends. This report includes market projections through 2025, detailing the market share for oncology diagnostics based on the product, application and end user.
By product, the oncology diagnostics market is segmented into diagnostic imaging, endoscopy, biopsy, immunohistochemistry, in situ hybridization, tumor biomarkers tests and others. By application, the oncology diagnostics market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer and others. By end-user, the oncology diagnostics market is segmented into hospitals, diagnostic imaging centers, research institutes and others.
By geography, the oncology diagnostics market has been segmented into Europe, North America, Asia Pacific (APAC) and the Rest of the World (RoW). The detailed analyses of major countries like the U.S., Germany, Canada, the UK, Spain, Italy, France, Japan, India and China are regional segments. For market estimates, data is provided for 2019 as the base year, 2020 and forecast through year-end 2025. Estimated values used are based on oncology diagnostic product manufacturers’ total revenues. Projected and forecast revenue values are in constant U.S. dollars that have not been adjusted for inflation.
The Report Includes
- 32 data tables and 19 additional tables
- An overview of the global markets for oncology diagnostics
- Estimation of the market size and analyses of market trends, with data from 2019 to 2020 and projection of CAGR through 2025
- Market share analysis of oncology diagnostics by application, product, end-user and region, and evaluation of market size and forecast, and detailed analysis of drivers, challenges and opportunities affecting the market growth
- Highlights of the current and future market potential of oncology diagnostics and a detailed analysis of the regulatory landscape, complications and prevalence of cancer
- Details of major advances in technologies and products, ongoing activities and pipeline analysis of new products in the oncology diagnostics industry
- Details about symptoms, progression and epidemiology of COVID-19 and discussion on the impact of COVID-19 pandemic on the medical industry as well as on oncology diagnostics market
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry, including Abbott, Agilent, bioMérieux, General Electric Co., Roche, Siemens and Thermo Fisher Scientific
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
- Highlights of the Market for Oncology Diagnostics
Chapter 3 Medical Device Regulations
- Medical Device Definition and Classification
- Regulations in the U.S.
- Legislation
- Regulations in Europe
- Process
- Regulations in Japan
Chapter 4 Oncology Diagnostics: Market Background
- Introduction
- Cancer
- Cancer Cells versus Normal Cells
- Types of Cancer
- Pipeline
Chapter 5 Oncology Diagnostics: Market Dynamics
- Market Dynamics
- Drivers
- Market Restraints
Chapter 6 Impact of COVID-19 Pandemic
- Introduction
- Outbreak
- Spread of Disease
- Impact on MedTech
- Elective and Noncritical Procedures
- Shift in Manufacturing
- Regulatory Delays, Clinical Trials and Product Launches
- Supply Chain Disruptions
- Medical Tourism
- Impact of COVID-19 on the Global Economy
- Government Expenditures on COVID-19
- Impact on Insurance Providers
- Impact of COVID-19 on Oncology
- Impact on Early Cancer Diagnosis
- Impact on Cancer Research
- COVID-19 and Reimagining Cancer Care
- Significant Declines in Testing and Diagnosis
- Public Health Impact of COVID-19 Across the Cancer Continuum
Chapter 7 Market Breakdown by Product Category
- Introduction
- Diagnostic Imaging
- Market Size and Forecast
- Market Analysis
- Endoscopy
- Market Size and Forecast
- Market Analysis
- Biopsies
- Market Size and Forecast
- Market Analysis
- Immunohistochemistry
- Market Size and Forecast
- Market Analysis
- In Situ Hybridization
- Market Size and Forecast
- Market Analysis
- Tumor Biomarker Tests
- Market Size and Forecast
- Market Analysis
- Others
- Market Size and Forecast
- Market Analysis
Chapter 8 Market Breakdown by Application
- Introduction
- Breast Cancer
- Market Size and Forecast
- Market Analysis
- Lung Cancer
- Market Size and Forecast
- Market Analysis
- Colorectal Cancer
- Market Size and Forecast
- Market Analysis
- Prostate Cancer
- Market Size and Forecast
- Market Analysis
- Liver Cancer
- Market Size and Forecast
- Market Analysis
- Other Cancers
- Market Size and Forecast
- Market Analysis
Chapter 9 Market Breakdown by End User
- Introduction
- Hospitals
- Market Size and Forecast
- Market Analysis
- Diagnostic Imaging Centers
- Market Size and Forecast
- Market Analysis
- Research Institutes
- Market Size and Forecast
- Market Analysis
- Other End Users
- Market Size and Forecast
- Market Analysis
Chapter 10 Market Breakdown by Region
- Introduction
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- Rest of the World
Chapter 11 Competitive Landscape
- Mergers and Acquisitions
- Strategic Alliances
Chapter 12 Company Profiles
- Abbott
- Agilent Technologies Inc.
- Biomerieux Sa
- Biocartis Nv
- Diasorin S.P.A.
- F. Hoffmann-La Roche Ag
- General Electric Co.
- Koninklijke Philips N.V.
- Siemens Healthcare Gmbh
- Thermo Fisher Scientific
Chapter 13 Appendix: List of Acronyms
List of Tables
Summary Table A: Global Market for Oncology Diagnostics, by Product Category, Through 2025
Summary Table B: Global Market for Oncology Diagnostics, by Application, Through 2025
Table 1: Class I and Class II 510(k) Exempt Devices
Table 2: Cancer Incidence and Mortality Statistics, by Region, 2020
Table 3: Global Elderly Population (60+ Years), by Country, 2019
Table 4: Cancer Incidence and Mortality, 65+ Population
Table 5: Expenditures on COVID-19 Crisis, by Selected Country
Table 6: Interim Economic Outlook Forecasts, by Country/Region, 2019-2021
Table 7: Global Market for Oncology Diagnostics, by Product Category, Through 2025
Table 8: Most Common Types of Endoscopy
Table 9: Characteristics of In Situ Hybridization Methods
Table 10: In Situ Hybridization Probe Types
Table 11: Common Types of Tumor Markers
Table 12: Global Market for Oncology Diagnostics, by Application, Through 2025
Table 13: Countries with the Highest Rates of Breast Cancer, 2018
Table 14: Countries with Highest Incidence of Lung Cancer, 2018
Table 15: Countries with the Highest Rates of Colorectal Cancer, 2018
Table 16: Countries with the Highest Rates of Prostate Cancer, 2018
Table 17: Countries with the Highest Rates of Liver Cancer, 2018
Table 18: Global Market for Oncology Diagnostics, by End User, Through 2025
Table 19: Selected Cancer Research Institutes
Table 20: Selected Cancer Research Funding Sources
Table 21: Global Market for Oncology Diagnostics, by Region, Through 2025
Table 22: North American Market for Oncology Diagnostics, by Country, Through 2025
Table 23: North American Market for Oncology Diagnostics, by Product Category, Through 2025
Table 24: North American Market for Oncology Diagnostics, by Application, Through 2025
Table 25: North American Market for Oncology Diagnostics, by End User, Through 2025
Table 26: New Cancer Cases in the U.S., by Cancer Site, 2021
Table 27: European Market for Oncology Diagnostics, by Country, Through 2025
Table 28: European Market for Oncology Diagnostics, by Product Category, Through 2025
Table 29: European Market for Oncology Diagnostics, by Application, Through 2025
Table 30: European Market for Oncology Diagnostics, by End User, Through 2025
Table 31: Asia-Pacific Market for Oncology Diagnostics, by Country, Through 2025
Table 32: Asia-Pacific Market for Oncology Diagnostics, by Product Category, Through 2025
Table 33: Asia-Pacific Market for Oncology Diagnostics, by Application, Through 2025
Table 34: Asia-Pacific Market for Oncology Diagnostics, by End User, Through 2025
Table 35: RoW Market for Oncology Diagnostics, by Product Category, Through 2025
Table 36: RoW Market for Oncology Diagnostics, by Application, Through 2025
Table 37: RoW Market for Oncology Diagnostics, by End User, Through 2025
Table 38: Leading Causes of Death in Argentina and Percentage Change, 2007-2017
Table 39: Abbott: Oncology Diagnostics Product Portfolio
Table 40: Agilent: Oncology Diagnostics Product Portfolio
Table 41: bioMérieux: Oncology Diagnostics Product Portfolio
Table 42: Biocartis: Oncology Diagnostics Product Portfolio
Table 43: DiaSorin Group: Oncology Diagnostics Product Portfolio
Table 44: Roche: Oncology Diagnostics Product Portfolio
Table 45: General Electric Co.: Oncology Diagnostics Product Portfolio
Table 46: Philips: Oncology Diagnostics Product Portfolio
Table 47: Siemens: Oncology Diagnostics Product Portfolio
Table 48: Thermo Fisher Scientific: Oncology Diagnostics Product Portfolio
Table 49: Acronyms Used in the Oncology Diagnostics Industry
List of Figures
Summary Figure A: Global Market for Oncology Diagnostics, by Product Category, 2019-2025
Summary Figure B: Global Market Share of Oncology Diagnostics, by Product Category, 2020
Summary Figure C: Global Market for Oncology Diagnostics, by Application, 2019-2025
Figure 1: Marketing a Medical Device in the U.S.
Figure 2: New Cases of the Most Common Types of Cancer, Globally, 2020
Figure 3: Cancer Prevalence, by Country, 2017-2020
Figure 4: Countries with the Highest Expected Percentage of People Aged 60+, 2050
Figure 5: Comparison of GDP Growth, by Country, 2019 and 2020
Figure 6: Potential Impact of the COVID-19 Pandemic on Future Cancer Outcomes
Figure 7: Global Market Share for Oncology Diagnostics, by Product Category, 2020
Figure 8: Global Market for Diagnostic Imaging, 2019-2025
Figure 9: Global Market for Endoscopy, 2019-2025
Figure 10: Global Market for Biopsies, 2019-2025
Figure 11: Global Market for Immunohistochemistry, 2019-2025
Figure 12: Global Market for In Situ Hybridization, 2019-2025
Figure 13: Global Market for Tumor Biomarker Tests, 2019-2025
Figure 14: Global Market for Other Types of Oncology Diagnostic Products, 2019-2025
Figure 15: Global Market Share for Oncology Diagnostics, by Application, 2020
Figure 16: Global Market for Breast Cancer Diagnostics for, 2019-2025
Figure 17: Global Market for Lung Cancer Diagnostics, 2019-2025
Figure 18: Global Market for Colorectal Cancer Diagnostics, 2019-2025
Figure 19: Global Market for Prostate Cancer Diagnostics, 2019-2025
Figure 20: Global Market for Liver Cancer Diagnostics, 2019-2025
Figure 21: Global Market for Oncology Diagnostics, Other Types of Cancer, 2019-2025
Figure 22: Global Market for Oncology Diagnostics, by End User, 2020
Figure 23: Global Market for Oncology Diagnostics in Hospitals, 2019-2025
Figure 24: Global Market for Oncology Diagnostics in Diagnostic Imaging Centers, 2019-2025
Figure 25: Global Market for Oncology Diagnostics in Research Institutes, 2019-2025
Figure 26: Global Market for Oncology Diagnostics for Other End Users, 2019-2025
Figure 27: Global Market Share for Oncology Diagnostics, by Region, 2020
Figure 28: North American Market Share for Oncology Diagnostics, by Country, 2020
Figure 29: The U.S. Market for Oncology Diagnostics, 2019-2025
Figure 30: Canadian Market for Oncology Diagnostics, 2019-2025
Figure 31: Number of New Cancer Cases in Canada, by Cancer Site, 2020
Figure 32: Share of New Cancer Cases in Canada, by Cancer Site, 2020
Figure 33: European Market Share for Oncology Diagnostics, by Country, 2020
Figure 34: German Market for Oncology Diagnostics, 2019-2025
Figure 35: Number of New Cases in Germany, by Cancer Site, 2020
Figure 36: Share of New Cancer Cases in Germany, by Cancer Site, 2020
Figure 37: UK Market for Oncology Diagnostics, 2019-2025
Figure 38: French Market for Oncology Diagnostics, 2019-2025
Figure 39: Number of New Cancer Cases in France, by Cancer Site, 2020
Figure 40: Share of New Cancer Cases in France, by Cancer Site, 2020
Figure 41: Italian Market for Oncology Diagnostics, 2019-2025
Figure 42: Number of New Cancer Cases in Italy, by Cancer Site, 2020
Figure 43: Share of New Cancer Cases in Italy, by Cancer Site, 2020
Figure 44: Spanish Market for Oncology Diagnostics, 2019-2025
Figure 45: Number of New Cancer Cases in Spain, by Cancer Site, 2020
Figure 46: Share of New Cancer Cases in Spain, by Cancer Site, 2020
Figure 47: Rest of European Market for Oncology Diagnostics, 2019-2025
Figure 48: Asia-Pacific Market Share for Oncology Diagnostics, by Country, 2020
Figure 49: Japanese Market for Oncology Diagnostics, 2019-2025
Figure 50: Number of New Cancer Cases in Japan, by Cancer Site, 2020
Figure 51: Share of New Cancer Cases in Japan, by Cancer Site, 2020
Figure 52: Chinese Market for Oncology Diagnostics, 2019-2025
Figure 53: Number of New Cancer Cases in China, by Cancer Site, 2020
Figure 54: Share of New Cancer Cases in China, by Cancer Site, 2020
Figure 55: Indian Market for Oncology Diagnostics, 2019-2025
Figure 56: Number of New Cancer Cases in India, by Cancer Site, 2020
Figure 57: Share of New Cancer Cases in India, by Cancer Site, 2020
Figure 58: Rest of Asia-Pacific Market for Oncology Diagnostics, 2019-2025
Figure 59: Rest of the World Market for Oncology Diagnostics, 2019-2025
Figure 60: Number of New Cancer Cases in Brazil, by Cancer Site, 2020
Figure 61: Share of New Cancer Cases in Brazil, by Cancer Site, 2020
Figure 62: New Cancer Cases in Africa, by Cancer Site, 2020
Figure 63: New Cancer Cases Share in Africa, by Cancer Site, 2020
Figure 64: Abbott: Annual Revenue, 2018-2020
Figure 65: Abbott: Revenue Share, by Country, 2020
Figure 66: Abbott: Revenue Share, by Business Segment, 2020
Figure 67: Agilent: Annual Revenue, 2018-2020
Figure 68: Agilent: Revenue Share, by Region, 2020
Figure 69: Agilent: Revenue Share, by Segment, 2020
Figure 70: DiaSorin Group: Annual Revenue, 2018 and 2019
Figure 71: DiaSorin Group: Revenue Share, by Region/Country, 2019
Figure 72: Roche: Revenue Share, by Business Segment, 2020
Figure 73: General Electric Co.: Annual Revenue, 2018-2020
Figure 74: General Electric Co.: Revenue Share, by Region/Country, 2020
Figure 75: General Electric Co.: Revenue Share, by Business Segment, 2020
Figure 76: Philips: Annual Revenue, 2018-2020
Figure 77: Philips: Revenue Share, by Region/Country, 2020
Figure 78: Philips: Revenue Share, by Business Segment, 2020
Figure 79: Siemens: Annual Revenue, 2019 and 2020
Figure 80: Siemens: Revenue Share, by Business Segment, 2020
Figure 81: Thermo Fisher Scientific: Annual Revenue, 2019 and 2020
Figure 82: Thermo Fisher Scientific: Revenue Share, by Business Segment, 2020
Executive Summary
The global market is growing due to the increasing prevalence of cancer, a rise in the world’s elder population, rising awareness and growing technological advancements in various fields: biomarkers, imaging, biopsy and endoscopy. Advances in science and technology platforms are expected to progress faster in oncology than in other disease areas, due to terminal disease prevalence and the corresponding rise in patient risk tolerance.
According to the WHO, cancer is the second leading cause of death, globally, accounting for around one in six deaths in 2018. Prostate, colorectal, stomach, lung and liver cancer are the most common types of cancer in men, while colorectal, breast, lung, cervical and thyroid cancer are the most common among women.
The cancer burden continues to rise, globally, exerting tremendous emotional, physical and financial strain on families, individuals, communities and health systems. Many health systems in low and middle-income countries are not prepared to manage this burden. Large numbers of cancer patients, worldwide, do not have access to timely quality treatment and diagnosis. In countries where health systems are robust, survival rates of many types of cancers are improving due to accessible early detection, quality treatment and survivorship care.
Delayed cancer treatment can result in a considerable decrease in survival. The oncology diagnostics market is booming and very competitive, with many big and small players operating in different market segments. A strong need for new diagnostic tools exists to allow earlier detection with higher specificity and higher sensitivity. New startups are founded every year with the aim of developing the next big diagnostic technology.
Healthcare facilities have adopted stricter safety practices to reduce the risk of exposing people to COVID-19. At the start of the coronavirus pandemic, elective medical procedures, including cancer diagnosis, were primarily put on hold to prioritize urgent needs and reduce the risk of the virus spread in healthcare settings. One result of this has been a substantial decline in cancer diagnosis and screening.
Many cancer diagnoses and treatment plans have been changed so that people do not have to spend as much time at these facilities. Many medical appointments are being spread out to avoid close contact between people. More appointments are being made over the phone or online and hospital stays after surgery have been shortened. In some cases, fewer in-person visits are required to complete chemotherapy or radiation therapy.
Companies Mentioned
- Abbott
- Agilent Technologies Inc.
- Biocartis Nv
- Biomerieux Sa
- Diasorin S.P.A.
- F. Hoffmann-La Roche Ag
- General Electric Co.
- Koninklijke Philips N.V.
- Siemens Healthcare Gmbh
- Thermo Fisher Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 174 |
| Published | May 2021 |
| Forecast Period | 2020 - 2025 |
| Estimated Market Value ( USD | $ 86.7 Billion |
| Forecasted Market Value ( USD | $ 128.3 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
